Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 2, 2014, Pages 88-92

  Gupta, Sandeep Kumar ^a   Nayak, Roopa Prasad ^a  

^a Department of Pharmacology Dhanalakshmi Srinivasan Medical College and Hospital ^*  (India)

Author keywords

Clinical trial; key opinion leaders; off label use; orphan disease; regulatory approval; risk benefit analysis

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; DEXFENFLURAMINE; FENFLURAMINE; GABAPENTIN; LETROZOLE; MITOMYCIN; PACLITAXEL; PHENTERMINE; PROPRANOLOL; RANIBIZUMAB; THALIDOMIDE;

ANGINA PECTORIS; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; COLON CANCER; COMPLEX REGIONAL PAIN SYNDROME; DIABETIC NEUROPATHY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; ERYTHEMA NODOSUM LEPROSUM; ESOPHAGUS CANCER; FEMALE INFERTILITY; HEALTH HAZARD; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG CARCINOMA; METASTATIC COLORECTAL CANCER; MIGRAINE; NEUROPATHIC PAIN; OFF LABEL DRUG USE; OVARY CANCER; PANCREAS CARCINOMA; PRESCRIPTION; RESTLESS LEGS SYNDROME; RETINA MACULA AGE RELATED DEGENERATION; RISK BENEFIT ANALYSIS; SEIZURE; SLEEP DISORDER; STOMACH CARCINOMA; UTERINE CERVIX CARCINOMA; VALVULAR HEART DISEASE;

EID: 84928029718     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.130046     Document Type: Article

References (25)

1. Fugh-Berman A, Melnick D. Off-label promotion, on-Target sales. PLoS Med 2008;5:e210
2. Stafford RS. Regulating off-label drug use-Rethinking the role of the FDA. N Engl J Med 2008;358:1427-9
3. Emmerich J, Dumarcet N, Lorence A. France's New Framework for Regulating Off-Label Drug Use. N Engl J Med 2012;367:1279-81
4. Field RI. The FDA's new guidance for off-label promotion is only a start. P T 2008;33:220-49
5. Tabarrok AT. Assessing the FDA via the anomaly of off-label drug prescribing. Indep Rev 2000;5:25-53
6. Maddin S. Off-label (unlabeled) Use of Drugs. Skin Therapy Letter 1998;4:1-6. Available from: Http://www.skintherapyletter.com/download/ stl-4-1.pdf [Last accessed on 2012 May 27
7. Klein DB, Tabarrok A. Do off-label drug practices argue against FDA efficacy requirements? A critical analysis of physicians' argumentation for initial efficacy requirements. Am J Econ Sociol 2008;67:743-75
8. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-Analyses of bevacizumab and ranibizumab: Off-label versus goldstandard. PLoS One 2012;7:e42701
9. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007;55:441-3
10. Santhan Gopal KS. Off with the label and on the Avastin bandwagon: Why now and how far? Indian J Ophthalmol 2009;57:253-6
11. WHO Model Lists of Essential Medicines. 18th ed. (April 2013). Accessed online from: Http://www.who.int/medicines/publications/ essentialmedicines/18th- EML-Final-web-8Jul13.pdf [Last accessed on 2013 August 23
12. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6
13. Sirven JI. New uses for older drugs: The tales of aspirin, thalidomide, and gabapentin. Mayo Clin Proc 2010;85:508-11
14. Dresser R, Frader J. Off-label prescribing: A call for heightened professional and government oversight. J Law Med Ethics 2009;37:476-86
15. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. PLoS Med 2011;8:e1000431
16. Hill P. Off licence and off label prescribing in children: Litigation fears for physicians. Arch Dis Child 2005;90 (Suppl 1):i17-8
17. Gota V, Patial P. Off-label use of anti-cancer drugs in India: To be or not to be! J Cancer Res Ther 2011;7:35-9
18. Fukada C, Kohler JC, Boon H, Austin Z, Krahn M. Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists. Can Pharm J (Ott) 2012;145:280-4.e1
19. Curtiss FR, Fairman KA. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U. S. Justice Department. J Manag Care Pharm 2009;15:161-5
20. Barlas S. Off-label drug promotion now on the table: House and senate voice concerns. P T 2008;33:73-5
21. Ventola CL. Off-label drug information: Regulation, distribution, evaluation, and related controversies. P T 2009;34:428-40
22. Guidance for Industry-Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices. Department of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Policy. January 2009. Accessed online from http://www.fda.gov/regulatoryinformation/ guidances/ucm125126.htm [Last accessed on 2012 May 25
23. Khamar B. Off-label use of medicines: Medical research and medical practice. Indian J Ophthalmol 2007;55:411-2
24. Ahmad K. Indian drug firm accused of illegal marketing of letrozole. Lancet Oncol 2003;4:647
25. Mudur G. Indian Medical Association wants off-label prescribing. BMJ 2004;328:974.